Molbio Diagnostics Ltd IPO - Check Issue Date, Price, Lot Size & Details with BlinkX.

Molbio Diagnostics Ltd IPO

We are an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and costeffective healthcare technologies to diagnose infectious and non-communicable diseases. Our portable and battery operated `Truenat' platform facilitates diagnosis using our disease-specific `Truenat' test kits within an hour and enables screening and diagnosis for 30 diseases, including tuberculosis, COVID, Hepatitis B and C, Human immunodeficiency virus, and Human Papillomavirus, as of March 31, 2025. We also offer devices, enabling radiology, digital pathology and breast health screening. We offer our products globally to public health programs, diagnostic laboratories, and private and public hospitals.

Molbio Diagnostics Ltd IPO Details

Total Shares Offered

₹ 1,16,44,314

Offer to Public

91,66,000

Retail Max (Shares)

₹ 40,69,005

Pre Issue Promoters Holding

₹ 5,25,97,450

Exchange

BSE

Issue size

₹ 939.7 Cr

IPO Open Date

Aug 10, 2026

Close Date

Aug 12, 2026

Lot Size

Min Investment

₹ 13,824

Issue Type

Book Building

Listing Date

Aug 17, 2026

Molbio Diagnostics Ltd IPO Dates

Aug 10, 2026

Opening date

Aug 12, 2026

Closing date

Aug 13, 2026

Basis of Allotment

Aug 14, 2026

Initiation of Refunds

Aug 14, 2026

Credit of Shares

Aug 17, 2026

Listing date

Details

Sector	Type
Sector	Healthcare
Sub Sector	NA
Issue Type	Book Building

Subscription Status

*Values are in Lakhs

Investor Type	Subscription Times	Shares Offered*
QIB	0x	5812863
NII	0x	1743859
Retail	0x	4069005
Employee	0x	18587
Total	0x	11644314

Investor Type

QIB

NII

Retail

Employee

Total

Subscription Times

5812863

1743859

4069005

18587

11644314

Molbio Diagnostics Ltd Financial Status

Income Statement

Particulars (In Rs. Crores)

Balance Sheet

Particulars (In Rs. Crores)

Particulars (in Rs. Crores)	FY23	FY22	FY21
Revenue from operations	1,020.42	836.56	332.46
EBITDA	240.66	199.09	61.63
PAT	139.82	111.11	15.55
Total Assets	870.68	747.80	617.54
Share Capital	2.26	2.25	2.25
Total Borrowings	139.35	102.24	149.88
Operating Activities (Net Cash)	166.13	134.71	34.94
Investing Activities (Net Cash)	77.75	52.21	53.79
Financing Activities (Net Cash)	139.35	102.24	149.88
Net Cashflow	110.77	18.26	4.58

About Molbio Diagnostics Ltd

Our Company was originally incorporated as `Molbio Diagnostics Private Limited' at Panaji, as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated October 20, 2000, issued by the RoC. Thereafter, our Company was converted from a private limited company to a public limited company, pursuant to a resolution passed in the extraordinary general meeting of our Shareholders held on November 22, 2024, and the name of our Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to our Company by the RoC.

The global point-of-care testing (POCT) market stands at Rs.2,350.8 billion (infectious and non-infectious diseases), projected to grow at 18.7% CAGR to reach at Rs.5,555.6 billion by 2029. Infectious disease testing constitutes 31.4% of the global POCT market. POCT market in India stands at approximately Rs.198.5 billion in Fiscal 2025, projected to grow at 17.3% CAGR to reach at approximately 440.9 billion by Fiscal 2030. Of which, the infectious POCT market is estimated to have a market potential of Rs.88.2 billion in Fiscal 2025 and is projected to reach Rs. 236.6 billion by Fiscal 2030.

Peer Comparison:

Poly Medicure Limited
Dr. Lal Pathlabs Limited
Metropolis Healthcare Limited
Vijaya Diagnostics Centre Limited

Molbio Diagnostics Ltd Key Points

Strengths

We are well placed to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.

Innovative, R&D focussed business.

We have developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.

We have a scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests.

Our strategic collaborations and acquisitions enhance our capabilities and offerings.

Risk

We derive a portion of our revenues from the sale of our products to the Indian central and state governments, and international aid agencies for their public healthcare programs. Our revenue from such government and international aid agencies was 84.56%, 87.83% and 91.60% of our revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. Any unfavourable policy changes by these agencies or a decrease in funding for public healthcare programs may impact the sale of our products and adversely affect our business, financial condition, results of operations and cash flows. Further, our revenue from the top 10 customers was 83.26%, 83.62% and 78.54% of our revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. The loss of any of these customers or a decline in demand for our products from them could also have an adverse effect on our business, financial condition, results of operations and cash flows.

We derive a portion of our revenues from the sale of diagnostic test kits for tuberculosis (TB). Our revenue from the sale of test kits for TB was 70.20%, 69.11% and 62.40% of our revenue from contracts with customers - sale of products - finished goods in the Fiscals 2026, 2025 and 2024, respectively. Any decline in the demand for such test kits may have an adverse effect on our business, financial condition, results of operation and cash flows.

We have invested and intend to continue to invest in research and development (R&D) efforts to grow our menu of tests. We cannot assure you that our R&D efforts will result in the successful development and obtaining of government approvals for new tests, which could adversely affect our business, results of operations, and cash flows.

Strategy

Expand our geographical presence in India and across the globe.

Continue to expand our suite of diagnostic solutions for multiple diseases.

Develop new POC platforms for other communicable and non-communicable diseases.

Grow through strategic acquisitions and alliances and establish a centre of excellence.

How To Apply for Molbio Diagnostics Ltd IPO Online?

Step 1:

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

FAQs on IPO (Initial Public Offering)

What is the issue size of the Molbio Diagnostics Ltd IPO?

Molbio Diagnostics Ltd's IPO offers shares for up to 200 It begins on Aug 10, 2026 and ends on Aug 12, 2026.

What is the price of the Molbio Diagnostics Ltd IPO?

The price of Molbio Diagnostics Ltd IPO ranges between ₹768 to ₹807 per share.

What are the open and close dates for the Molbio Diagnostics Ltd IPO?

The Molbio Diagnostics Ltd IPO opens on Aug 10, 2026 and closes on Aug 12, 2026.

When will the Molbio Diagnostics Ltd IPO be allotted?

The allotment for the Molbio Diagnostics Ltd IPO will be finalised on Aug 13, 2026. The shares will be listed on BSE and NSE on Aug 17, 2026.

What is the minimum lot size required for Molbio Diagnostics Ltd IPO?

The minimum lot size for Molbio Diagnostics Ltd IPO is 18 shares, priced between ₹768 to ₹807 per share.

What is the GMP of Molbio Diagnostics Ltd IPO?

The GMP (Grey Market Premium) of Molbio Diagnostics Ltd IPO fluctuates based on market demand and sentiment.

How do you check the allotment status of Molbio Diagnostics Ltd IPO?

To check the allotment status of Molbio Diagnostics Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

Where is the Molbio Diagnostics Ltd IPO getting listed?

The Molbio Diagnostics Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Aug 10, 2026, and closes on Aug 12, 2026. The allotment is finalised on Aug 13, 2026.

How do you apply for the Molbio Diagnostics Ltd IPO?

To apply for the Molbio Diagnostics Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.